Form 4: Akari Therapeutics CFO Acquires Warrants in Private Placement

Akari Therapeutics' Interim CFO, Kameel D. Farag, acquired pre-funded warrants and Series G warrants to purchase American Depositary Shares in a private placement transaction.

Summary

• Interim CFO Kameel D. Farag acquired 24,745 unregistered pre-funded warrants (PIPE PFWs) and 24,745 accompanying Series G Warrants.
• The acquisition occurred on December 16, 2025, through a private placement transaction, pursuant to an exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933.
• The combined purchase price for one PIPE PFW and one accompanying Series G Warrant was $0.4041.
• The PIPE PFWs have an exercise price of $0.00001 per American Depositary Share (ADS).
• The Series G Warrants have an exercise price of $0.3883 per ADS.
• Both types of warrants are exercisable upon shareholder approval.
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares of Akari Therapeutics Plc.

Sentiment

Score: 6

Explanation: The acquisition of warrants by an interim CFO generally indicates confidence in the company's future, which is a positive signal. However, the future transaction date and the contingency of shareholder approval introduce some uncertainty.

Positives

• An officer (Interim CFO) is increasing their beneficial ownership in the company, which can signal confidence in future prospects.
• The acquisition was part of a private placement, which can be a more efficient way for companies to raise capital.

Negatives

• The transaction date is listed as December 16, 2025, which is a future date and highly unusual for a Form 4 filing that typically reports past transactions.
• The exercisability of both the Series G Warrants and the PIPE PFWs is contingent upon obtaining shareholder approval, introducing a potential delay or uncertainty.

Risks

• The exercisability of the warrants is contingent on shareholder approval, which is not guaranteed and could impact the timing and realization of their value.
• The value of the warrants is dependent on the future performance of Akari Therapeutics' American Depositary Shares, exposing the holder to market risk.
• As unregistered securities acquired in a private placement, these warrants may have limitations on resale, affecting liquidity.

Future Outlook

The warrants are exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. This indicates a future period for potential exercise and conversion into American Depositary Shares.

Industry Context

This is an insider transaction, a common occurrence across all industries. The specific details, such as the acquisition of warrants in a private placement, are typical for smaller biotechnology companies seeking to raise capital or incentivize management, aligning their interests with shareholders.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider transaction. The acquisition of warrants by an officer is a common incentive mechanism, particularly in growth-oriented or early-stage companies like those in the biotechnology sector.
• The use of private placements for warrant issuance is also a common method for capital raising or strategic investment, often utilized by companies that may not have immediate access to public markets for equity offerings.

Related Party Transactions

• Interim CFO Kameel D. Farag acquired warrants from Akari Therapeutics Plc in a private placement transaction, which constitutes a related party dealing.

Stakeholder Impact

• Shareholders: Potential future dilution if the warrants are exercised, but also a signal of management confidence in the company's prospects. Shareholder approval is required for the warrants to become exercisable.
• Management: The Interim CFO increases their beneficial ownership, further aligning their financial interests with those of the company's shareholders.

Next Steps

• Shareholder approval is required for the warrants to become exercisable.
• The Series G Warrants will have a five-year term from the date of shareholder approval.
• The PIPE PFWs will remain exercisable until fully exercised.

Key Dates

Keywords

Akari Therapeutics, AKTX, Form 4, Insider Transaction, Warrants, Pre-Funded Warrants, Private Placement, Officer Acquisition, Beneficial Ownership, Biotechnology, Pharmaceuticals